VNDA = Biotech with potential big move up this month.

AI Summary

Author picks Vanda Pharma as a small-cap biotech with a February 21 FDA decision on Bysanti as a near-term catalyst.

VNDA — LONG The author identifies Vanda Pharma as his single stock pick among biotechs with potential milestone events this month, citing its growing commercial base with Fanapt and the recent Nereus trapitant approval for motion sickness. The key catalyst is the February 21 FDA decision date for Bysanti, a new antipsychotic for bipolar I disorder and schizophrenia, which would expand VNDA's commercial portfolio into a larger psychiatric market. He notes the company is well funded with $263.8 million, reducing near-term dilution risk, and sees multiple catalysts in 2026.

Target decision date for FDA is date is Feb 21st for Bysantii which is a new antipsychotic for bipolar I disorder and schizophrenia

Score 1

Comments 4

▶ Full Post Text

Ideas

u/MannerProfessional24 Reddit r/stocks

Long VNDA on Feb 21 Bysanti FDA decision

The author identifies Vanda Pharma as his single stock pick among biotechs with potential milestone events this month, citing its growing commercial base with Fanapt and the recent Nereus trapitant approval for motion sickness. The key catalyst is the February 21 FDA decision date for Bysanti, a new antipsychotic for bipolar I disorder and schizophrenia, which would expand VNDA's commercial portfolio into a larger psychiatric market. He notes the company is well funded with $263.8 million, reducing near-term dilution risk, and sees multiple catalysts in 2026.

▶ Full Post Text

Ideas

More from Reddit — r/stocks